Filing Flows › Interpace Biosciences (IDXG) › Gross margin
Interpace Biosciences (IDXG) gross margin by quarter
Interpace Biosciences' gross margin was 61.9% in Q2 2026 (second quarter 2026), -3.5 pts from Q1 2026. Over the last 6 quarters it ranged from 61.9% (Q2 2026) to 65.5% (Q4 2025).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | 61.9% | -3.5 pts | — |
| Q1 2026 | 65.4% | -0.2 pts | +1.4 pts |
| Q4 2025 | 65.5% | +3.4 pts | +1.8 pts |
| Q3 2025 | 62.1% | -1.9 pts | — |
| Q1 2025 | 64.0% | +0.3 pts | — |
| Q4 2024 | 63.7% | — | — |
Q2 2026 at a glance
Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%, net earnings $158K, operating cash flow $98K. The chart follows the revenue to costs, profit and cash.
Questions
What is Interpace Biosciences' gross margin?
Interpace Biosciences' gross margin was 61.9% in Q2 2026 (second quarter 2026), -3.5 pts from Q1 2026.
How has Interpace Biosciences' gross margin changed?
Over the last 6 quarters it ranged from 61.9% (Q2 2026) to 65.5% (Q4 2025).